These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 30359792)

  • 1. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
    Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
    Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
    Yamaguchi T; Shimizu J; Matsuzawa R; Watanabe N; Horio Y; Fujiwara Y
    BMC Cancer; 2024 Jul; 24(1):842. PubMed ID: 39009968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of genomic changes on treatment of lung cancer.
    Cardarella S; Johnson BE
    Am J Respir Crit Care Med; 2013 Oct; 188(7):770-5. PubMed ID: 23841470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
    Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
    J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.
    Lambros L; Guibourg B; Uguen A
    Clin Lung Cancer; 2018 Jan; 19(1):e73-e74. PubMed ID: 28919190
    [No Abstract]   [Full Text] [Related]  

  • 8. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Garrido P; Conde E; de Castro J; Gómez-Román JJ; Felip E; Pijuan L; Isla D; Sanz J; Paz-Ares L; López-Ríos F
    Clin Transl Oncol; 2020 Jul; 22(7):989-1003. PubMed ID: 31598903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
    Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
    Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
    López-Ríos F; Paz-Ares L; Sanz J; Isla D; Pijuan L; Felip E; Gómez-Román JJ; de Castro J; Conde E; Garrido P
    Rev Esp Patol; 2020; 53(3):167-181. PubMed ID: 32650968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of oncogene-driven non-small cell lung cancer.
    Kastelijn EA; de Langen AJ; Peters BJM
    Curr Opin Pulm Med; 2019 May; 25(3):300-307. PubMed ID: 30865033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ; Haslam A; Gill J; Prasad V
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
    Asao T; Takahashi F; Takahashi K
    Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
    Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
    J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.
    Qin H; Yan H; Chen Y; Xu Q; Huang Z; Jiang W; Wang Z; Deng L; Zhang X; Zhang L; Yang N; Zeng L; Zhang Y
    BMC Cancer; 2024 Aug; 24(1):952. PubMed ID: 39097705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis of peripheral non-squamous non-small cell lung cancer sampled by radial EBUS.
    Guisier F; Salaün M; Lachkar S; Lamy A; Piton N; Obstoy B; Sabourin JC; Thiberville L
    Respirology; 2016 May; 21(4):718-26. PubMed ID: 27099101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Going beyond EGFR.
    Zimmermann S; Peters S
    Ann Oncol; 2012 Sep; 23 Suppl 10():x197-203. PubMed ID: 22987962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.
    Marchal M; Leroy V; Behal H; Dansin E; Paris N; Bordier S; Humez S; Escande F; Gauvain C; Cortot AB
    Target Oncol; 2023 Nov; 18(6):927-939. PubMed ID: 37921939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid molecular profiling utilising minimal quantities of endobronchial ultrasound-guided aspirates for the detection of Epidermal Growth Factor Receptor, KRAS, ALK, ROS1, RET, NTRK and MET gene alterations from patients with non-small-cell lung carcinomas on the Biocartis Idylla™ platform.
    Haragan A; Lee R
    Cytopathology; 2024 Sep; 35(5):648-653. PubMed ID: 38814131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.